Research progress on indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
10.16438/j.0513-4870.2020-1421
- VernacularTitle:吲哚胺2,3-双加氧酶1 (IDO1) 抑制剂的研究进展
- Author:
Ting WANG
;
Hui WEN
;
Hua-qing CUI
;
Da-li YIN
- Publication Type:Research Article
- Keywords:
indoleamine 2,3-dioxygenase 1;
tryptophan;
tumor;
immune escape;
IDO1 inhibitor
- From:
Acta Pharmaceutica Sinica
2021;56(3):723-733
- CountryChina
- Language:Chinese
-
Abstract:
Indoleamine 2,3-dioxygenase 1 (IDO1) is the rate-limiting enzyme in the degradation of tryptophan to kynurenine. IDO1 is highly expressed in some tumor tissues. IDO1 can deplete tryptophan in tumor microenvironment, inhibit T cell function, and mediate the immune escape of tumor cells. Thus, IDO1 is considered a potential target of tumor immunotherapy. Currently, there are several IDO1 inhibitors in clinical research studies. The mechanism of IDO1-mediated tumor immune escape and the structure of IDO1 inhibitors are summarized in this review.
